• Decision making in healthcare and, specifically, in decision related to include or not an orphan drug by the NHS, requires a standardised process. This process requires transparency, consistency, and accountability to be perceived as legitimate by the public and health care providers to increase the likelihood of making right decisions.
A final MCDA framework specific for ODs was developed and validated to be used for the ODs evaluations conducted by the CatSalut. The test of the three OD through the developed framework specific for OD showed that MCDA can be considered a useful methodology which adds transparency, standardisation and allows a structured discussion that substantiates decision making adopted by the committee. • In the validation phase, some criteria were removed ("size of population", "type of preventive benefit", "non-medical costs", "mandate and scope of healthcare system", "environmental impact", "political/historical/cultural context") or adapted ("therapeutic benefit") from the standard framework based on EVIDEM (v.4.0) for CatSalut purposes.
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DEVELOPMENT OF AN EVALUATION FRAMEWORK FOR ORPHAN DRUGS BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR HEALTH CARE DECISION MAKING IN CATALONIA
• Figure 1 shows the final version of the MCDA framework adapted to ODs evaluation by CatSalut members and figure 2 shows the weights of the final framework criteria through a direct rating scale (from 0, less important to 5, most important). Criteria considered more important
MCDA framework adapted to ODs evaluation
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• The assessment of 3 ODs was conducted to rate the evidence matrix. Figure 3 shows the results of the assessment of alpha-1-antitrypsin (A), eliglustat (B) and tolvaptan (C). The reflective discussion was perceived as very relevant to support inputs for health decision-making processes, reflecting drug value, positioning the 3 ODs within the different dimensions and finally discussing the overall value of the drug by CatSalut. Fig.3 . Results of value contribution of the 3 ODs according to quantitative criteria of the EVIDEM framework adapted to ODs evaluation and percentages of experts who scored neutrally, negatively of positively the impact of the 3 ODs in contextual criteria.
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